Lanean...
Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer
BACKGROUND: Complete surgical resection of breast cancer is a powerful determinant of patient outcome, and failure to achieve negative margins results in reoperation in between 30% and 60% of patients. We hypothesize that repurposing Food and Drug Administration approved antibodies as tumor-targetin...
Gorde:
| Argitaratua izan da: | J Surg Res |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2013
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4354808/ https://ncbi.nlm.nih.gov/pubmed/24360117 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jss.2013.11.1089 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|